HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study.

AbstractPURPOSE:
To evaluate the dynamics and feasibility of imaging non-small cell lung cancer (NSCLC) apoptosis induced by paclitaxel treatment using 99mTc-labeled C2A domain of synaptotagmin I in a mouse model.
MATERIALS AND METHODS:
H460 tumor-bearing mice were treated with intravenous paclitaxel, and 12, 24, 48 and 72 h later, 99mTc-C2A-GST was injected intravenously, and planar images were acquired at 2, 4 and 6 h postinjection on a dual-head gamma camera fitted with a pinhole collimator. Tumor-to-normal tissue ratios (T/NT) were calculated by ROI analysis and reflected specific binding of 99mTc-C2A-GST. Mice were sacrificed after 6-h imaging; caspase-3 as apoptosis executer was determined by flow cytometry; DNA fragmentation was analyzed by terminal deoxynucleotidytransferase mediated dUTP nick-end labeling (TUNEL) assay. Whereas nonspecific accumulation was estimated using inactivated C2A-GST. The imaging data were correlated with TUNEL-positive nuclei and caspase-3 activity.
RESULTS:
T/NT significantly increased after paclitaxel inducement, whereas it was low in untreated tumors (T/NT=1.24+/-0.23). In terms of % ID/g, activity in Group 2 (12 h), Group 3 (24 h), Group 4 (48 h) and Group 5 (72 h) after the treatment was 2.05+/-0.20, 3.02+/-1.01, 3.17+/-1.16 and 3.96+/-1.72, respectively. Whereas in the nontreated group, Group 1 % ID/g was 1.21+/-0.51. The radiotracer uptake was positively correlated to the apoptotic index (r=0.70, P<.01), as well as caspase-3 activity (r=0.75, P<.01).
CONCLUSION:
This study addresses the dynamics and feasibility of imaging non-small cell lung tumor apoptosis using 99mTc-labeled C2A.
AuthorsFeng Wang, Wei Fang, Ming Zhao, Zizheng Wang, Shundong Ji, Yan Li, Yuming Zheng
JournalNuclear medicine and biology (Nucl Med Biol) Vol. 35 Issue 3 Pg. 359-64 (Apr 2008) ISSN: 0969-8051 [Print] United States
PMID18355692 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Radiopharmaceuticals
  • Synaptotagmin I
  • Technetium
  • Casp3 protein, mouse
  • Caspase 3
  • Paclitaxel
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (therapeutic use)
  • Apoptosis (drug effects)
  • Carcinoma, Non-Small-Cell Lung (diagnostic imaging, drug therapy)
  • Caspase 3 (drug effects, metabolism)
  • Cell Line, Tumor
  • DNA Fragmentation (drug effects)
  • Disease Models, Animal
  • Female
  • Humans
  • Injections, Intravenous
  • Lung Neoplasms (diagnostic imaging, drug therapy)
  • Male
  • Mice
  • Paclitaxel (therapeutic use)
  • Protein Structure, Tertiary
  • Radioligand Assay (methods)
  • Radionuclide Imaging
  • Radiopharmaceuticals (pharmacokinetics)
  • Synaptotagmin I (chemistry, drug effects)
  • Technetium (pharmacokinetics)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: